General Information
| Application | Inhibitor |
|---|
| Description | Amcasertib (BBI503), a first-in-class cancer stemness kinase inhibitor, is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity. |
|---|
| Cas NO. |
1129403-56-0 |
|---|
| Purity | ≥98% |
|---|---|
| Molecular Weight | 539.69 |
| Formula | C31H33N5O2S |
| Solubility |
DMSO : 14 mg/mL Ethanol : 1 mg/mL Water : Insoluble |
|---|
| Target / IC50 |
Nanog |
|---|
| Storage |
Powder : -20°C for 3 years Solvent : -80°C for 6 months |
|---|
| Alias |
BBI503 |
|---|
|
|
1 mg |
5 mg |
10 mg |
|
|
1 mM |
1.8529 mL | 9.2646 mL | 18.5292 mL | |
| 5 mM | 0.3706 mL | 1.8529 mL | 3.7058 mL | |
| 10 mM | 0.1853 mL | 0.9265 mL | 1.8529 mL | |
.png)